Copy

A Message From Dr. Young

Dear Valued Patients, Friends and Colleagues,

We hope that you are enjoying the gorgeous summer in the beautiful Pacific Northwest!

We are excited to introduce a new member who has recently joined our practice – Ms Maria Ramos Martinez!

Maria has been a licensed Certified Medical Assistant for more than 6 years. She has experience as a medical assistant in general dermatology, dermatologic surgery, phototherapy (including photodynamic therapy and XTRAC excimer laser treatment) and cosmetic dermatology. She is trained in HIPAA privacy rule compliance and is skilled in the use of electronic medical records. Maria is responsible, diligent, energetic, and an incredibly fast learner. She has a strong work ethic and is a team player who puts others’ needs above hers.

Please join us in welcoming Maria to our family!

Sincerely,
Alison Young, MD PhD

Please Follow Us Online!

Facebook
Instagram
Website

Our August Offer!

Purchase 2 syringes of any Juvederm filler
Get one 0.55 syringe of Volbella Free plus $75.00 off of the price for the above 2 syringes. In addition, get double points on the filler. On top of all that receive $120 in Alle points to use on your next visit.

Procedure & Product of the Month

Keralase™, Lutronic Ultra™ & KeraFactor™

Keralase™ is a treatment for hair loss, utilizing a fractional 1927nm laser which acts as an efficient topical delivery system for a proprietary growth factor solution (KeraFactor™), producing statistically significant results for both hair density and hair diameter, and clinically apparent hair growth with patient satisfaction that lasts until the six-month follow-up. The treatment is comfortable, fast, with no downtime. A total of six treatments, spaced 2 weeks apart, are recommended.

Lutronic Ultra™ (fractional 1927nm Thulium) laser is first used to prepare the scalp, to create microchannels, enhance scalp microvasculature and optimize the absorption of KeraFactor™.

KeraFactor™ serum contains 7 bioidentical growth factors specifically selected to combat and treat the visible signs of hair loss. The growth factors are delivered in a nanoliposomal carrier to increase absorption. KeraFactor™ promotes hair rejuvenation, boosting scalp skin and hair appearance, and revitalizes resting hair follicles, leading to visibly fuller, thicker, healthier-looking hair.

In recent years, platelet-rich plasma (PRP) injection has gained popularity in the treatment of hair loss. PRP contains growth factors that are used for wound healing, including some that also stimulate certain portions of the hair life cycle. Although many patients have improvement with these treatments, the variables or incomplete response leads them to seek alternative or additional therapies. I find Keralase™ combined with KeraFactor™ application to be a consistent and painless method in enhancing hair growth and scalp health. – Dr Young

Dr. Young is excited to partner with Fullscript to give her patients access to high quality supplementations from the safety of their own homes.  Look out for the Cyber Monday sale coming soon.  

Fullscript is a smart, easy way to access supplements and meet wellness goals – from anywhere.  You can pick your favourite supplements from your preferred device, and supplements get shipped right to your front door. Plus, getting started is completely free! It’s that simple.
Click Here for Fullscript

Did You Know?

New-Onset Skin Disease Following COVID-19 May Resolve Spontaneously Without Medication, Systematic Review Suggests

Dermatology Advisor (8/4, Goldberg) reports, “New-onset skin disease following COVID-19 infection can resolve spontaneously without medication, and the most common of such diseases is telogen effluvium...according to findings from a systematic review letter-to-the-editor published in The Journal of Dermatology.” The findings also noted that “neither exacerbations nor new-onset of chilblains, urticaria, vasculitis, or livedo lesions are anticipated following COVID-19 infection.”

We continue to observe hair loss (telogen effluvium), and skin eruptions ranging from hives (urticaria), eczema to bruise-like lesions (vasculitis or livedo reticularis) following COVID-19 infection. Reassuringly, most of these skin reactions resolve spontaneously without medication. – Dr Young
 

Adverse Skin Reactions Rare, Generally Mild Following COVID-19 Vaccination, Research Shows

HCPlive (8/4, Walter) reported research “shows adverse skin reactions are rare and generally mild following a COVID-19 vaccination.” Investigators “identified 132 cases of adverse skin reactions following a COVID-19 vaccination dose between January 2021 and January 2022,” revealing that “urticaria-like rashes were the most common adverse skin reactions at 40.15% of the total reactions, followed by eczema-like rashes at 27.27%.” The findings were published in Dermatologic Therapy.
 
Apart from injection site reaction, the most common forms of skin reaction following COVID-19 vaccination are hives (urticaria) and eczema, which are usually mild and self-limiting, lasting 2 weeks to one month. – Dr Young

NEWS FLASH!

FDA approves first vitiligo treatment for skin repigmentation

The FDA has approved topical ruxolitinib (Opzelura) for the treatment of nonsegmental vitiligo in patients aged 12 years or older. The cream formulation of ruxolitinib — a Janus kinase (JAK) 1/JAK 2 inhibitor — was first approved in September 2021 for the treatment of mild-to-moderate atopic dermatitis (eczema). Previously, no treatment was approved to repigment patients with vitiligo.

Dr. Young's Tip of the Month

Monkeypox Q&A

What is monkeypox?

Monkeypox is caused by the monkeypox virus, which belongs to the Orthopoxvirus genus in the family Poxviridae. Though monkeypox is rare, it is endemic in Central and West African countries. There are two distinctive clades of the virus: the West African and the Congo Basin (or Central African). The Congo Basin clade (a group of similar viruses based on genetic sequences) is thought to cause more severe disease and be more lethal than the West African clade. The current virus seen in cases in the U.S. is the less severe West African clade. Despite the name, the reservoir species for monkeypox is unknown, though non-human primates remain susceptible to the disease, along with many other mammals including rodents. The most recent prior U.S. outbreak in 2003 was traced to infected prairie dogs, and there are concerns that if this outbreak is able to infect rodents, a persistent reservoir could develop leading to ongoing sporadic outbreaks in the future. Monkeypox can be transmitted from animal to human (zoonotic) or human to human. Transmission can occur through large respiratory droplets (theoretical risk of airborne transmission but not as contagious as SARS-CoV-2), body fluids, skin lesions (contact), and contaminated items. Contact during sex can spread monkeypox, but it is not classically a sexually transmitted disease — it is simply that during sex, there is skin to skin contact and shared air.

What are the symptoms of monkeypox?

Within 1-3 days after fever appears, patients develop a rash. This rash generally starts on the face and extremities (including palms and soles of the feet), and spreads to other parts of the body. The rash evolves from macules, to papules, to vesicles, to pustules before scabbing and eventually crusting over. Lesions are often noted in the oral mucous membranes and can cause difficulties with drinking and eating. These can also develop in the conjunctivae and cornea, as well as groin and genitals. It has been reported that patients in the current monkeypox outbreak have presented differently, with minimal symptoms prior to rash development, and rash originating in the groin area. Confirmed cases of monkeypox should be isolated until lesions have crusted over and a fresh layer of skin has formed underneath. Pitted scars, hyperpigmentation and/or hypopigmentation skin may remain after the crusts have fallen off. Once all crusts have fallen off, a person is no longer contagious. Generally, the duration of diseases is between 2-4 weeks.

Are there vaccines for monkeypox?

The virus that causes smallpox (variola virus) also belongs to the family Poxviridae. Like monkeypox virus, variola virus belongs to the genus Orthopoxvirus. Individuals who are vaccinated for smallpox may be at reduced risk for monkeypox. Routine vaccination for smallpox was halted in the U.S. in 1972, and most individuals under the age of 50 are unvaccinated. The smallpox vaccination has been shown to be approximately 85% effective in preventing monkeypox, however the number of people who have received this has declined since the eradication of smallpox. There is currently one FDA approved vaccine for the prevention of monkeypox (JYNNEOS), which is currently under evaluation for the protection of individuals at increased risk of exposure to orthopoxviruses.
 

Is there any treatment for monkeypox?

There is no specific treatment FDA-approved for monkeypox at this time. Symptoms usually resolve on their own, though patients should take care of their rash by allowing it to dry or applying a moist dressing. There are currently several experimental antiviral treatments for monkeypox, though there is limited data as to who may benefit from these treatments.
 

How does the West African clade variant of monkeypox death rate compare to smallpox?

Historically, the case-fatality rate of smallpox was estimated to be as high as 30%. In comparison, the case-fatality rate of the West African clade of monkeypox is estimated to be 3.6%, but there have been no reported deaths in recent U.S. outbreaks, possibly due to the level of supportive care available.
 

How long after vaccination is the smallpox vaccine effective against monkeypox? Is the protection lifelong?

In individuals historically vaccinated for smallpox with the Dryvax vaccine, immunity may be maintained for up to 75 years against smallpox. Research has shown that the duration of monkeypox immunity from the smallpox vaccination varies, but some level of protection may be offered long after an individual has been vaccinated.

At what point does an individual with monkeypox become infectious to others — incubation, systemic symptoms such as fever, or only once the rash develops?

According to the CDC, individuals are not contagious during the incubation period. Individuals may be contagious during initial symptom onset and are contagious from the rash phase of the disease until the lesions are completely crusted over.

Instagram
Facebook
LinkedIn
Website
Copyright ©  2022 Young Dermatology, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.